Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Myriad Genetics's profit margin for the twelve months ending Jun 30, 2026 was -14.0%. For fiscal 2025 it was -44.4%, against -15.2% the year before. The highest annual figure on record is 42.0% in fiscal 2010.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -44.4% | −29.2 |
| FY2024 | Dec 31, 2024 | -15.2% | +19.8 |
| FY2023 | Dec 31, 2023 | -35.0% | −18.4 |
| FY2022 | Dec 31, 2022 | -16.5% | +14.7 |
| FY2020 | Jun 30, 2020 | -31.2% | −31.8 |
| FY2019 | Jun 30, 2019 | 0.5% | −17.4 |
| FY2018 | Jun 30, 2018 | 17.9% | +15.5 |
| FY2017 | Jun 30, 2017 | 2.4% | −13.4 |
| FY2016 | Jun 30, 2016 | 15.8% | +4.8 |
| FY2015 | Jun 30, 2015 | 11.0% | −11.6 |
| FY2014 | Jun 30, 2014 | 22.6% | −1.4 |
| FY2013 | Jun 30, 2013 | 24.0% | +1.4 |
| FY2012 | Jun 30, 2012 | 22.6% | −2.4 |
| FY2011 | Jun 30, 2011 | 25.0% | −17.0 |
| FY2010 | Jun 30, 2010 | 42.0% | +16.1 |
| FY2009 | Jun 30, 2009 | 25.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -22.7% | +132.4 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -17.0% | −17.0 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -3.8% | +16.4 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -13.3% | −3.0 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -155.1% | −137.7 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -0.1% | +12.8 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -20.2% | −4.3 |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -10.4% | +21.6 |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -17.4% | +45.9 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -12.9% | +17.3 |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -15.9% | +7.9 |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -31.9% | −9.5 |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -63.3% | −55.4 |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -30.2% | −17.8 |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -23.8% | +35.7 |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -22.4% | +47.8 |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -7.9% | −3.6 |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -12.4% | −1.4 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -59.4% | −57.5 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -70.2% | −73.4 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -4.3% | −5.5 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -11.1% | −10.7 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -1.9% | −9.4 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | 3.2% | −1.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | 1.2% | −15.2 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -0.3% | −44.4 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 7.5% | +1.3 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | 5.0% | +3.5 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | 16.4% | +13.3 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | 44.1% | +44.5 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | 6.2% | −2.6 |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | 1.4% | −16.7 |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | 3.1% | −16.1 |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -0.4% | −16.9 |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | 8.8% | −0.9 |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | 18.1% | +6.2 |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | 19.2% | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | 16.5% | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | 9.7% | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | 11.9% | – |
See a number that looks wrong?